ArticleGastro hep advances2026
CATS-BIT-ME Score: A Machine Learning and Conventional Risk Model for Prognosis in Hepatocellular Carcinoma.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The prognosis of hepatocellular carcinoma (HCC) is influenced by various factors. This study aimed to develop and validate a novel machine learning (ML)-based risk score to stratify HCC patients into prognostic groups and compare its predictive accuracy with conventional staging systems and biomarkers. Methods: This retrospective study included 4038 HCC patients diagnosed between 2012 and 2023. Patients were randomly divided into training (n = 2827) and validation (n = 1211) cohorts in a 7:3 ratio. Prognostic factors for overall survival were identified using conventional Cox proportional hazards models and ML-based least absolute shrinkage and selection operator Cox regression. Variables significant in both methods were incorporated into a risk score, with each parameter scaled from 0 to 100, based on multivariable Cox regression coefficients. Patients were categorized into 3 risk groups using the 33rd and 66th percentiles. Results: After a median follow-up of 42 months (interquartile range: 33.6-50.4), 1931 deaths occurred, with a 5-year overall survival rate of 26.0%. Eleven significant prognostic variables were identified: age, maximum tumor size, extrahepatic metastasis, macrovascular invasion, serum albumin, bilirubin, creatinine, aspartate aminotransferase, lymphocyte-to-monocyte ratio, alpha-fetoprotein level, and treatment modality. The CATS-BIT-ME score demonstrated high predictive accuracy for overall survival (area under the receiver operating characteristic curve: 0.800) and effective risk stratification within the 5 years (area under the receiver operating characteristic curve range: 0.852-0.884). It outperformed 13 conventional staging systems and biomarkers in prognostic precision. Conclusion: The ML-based CATS-BIT-ME score provides an accurate and reliable tool for stratifying HCC patients into distinct prognostic groups, enhancing personalized disease management and clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.